PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.28%
Some net income increase while AVXL is negative at -26.59%. John Neff would see a short-term edge over the struggling competitor.
720.76%
D&A growth of 720.76% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
100.00%
Deferred tax of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-18.24%
Negative yoy SBC while AVXL is 38.58%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-114.66%
Negative yoy working capital usage while AVXL is 345.55%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-121.66%
Negative yoy AP while AVXL is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
139.41%
Lower 'other working capital' growth vs. AVXL's 345.55%. David Dodd would see fewer unexpected short-term demands on cash.
-139.67%
Negative yoy while AVXL is 162.04%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-28.06%
Both yoy CFO lines are negative, with AVXL at -2.64%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-383.87%
Negative yoy CapEx while AVXL is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-383.87%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-88.00%
Negative yoy issuance while AVXL is 65.21%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.